<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04911751</url>
  </required_header>
  <id_info>
    <org_study_id>KBL-CURE-2020-02</org_study_id>
    <nct_id>NCT04911751</nct_id>
  </id_info>
  <brief_title>A Study to Investigate Efficacy and Safety of KBL697 in Patients With Moderate Plaque Type Psoriasis</brief_title>
  <official_title>A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of KBL697 in Patients With Moderate Plaque Type Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KoBioLabs</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KoBioLabs</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to investigate efficacy and safety of KBL697 in patients with Moderate&#xD;
      Plaque Type Psoriasis. KBL697 has been developed as a potential new treatment for Psoriatic&#xD;
      Plaque.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Psoriasis Area and Severity Index (PASI)</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change from Baseline in PASI score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Area and Severity Index (PASI)</measure>
    <time_frame>Baseline to Weeks 2, 4 and 8</time_frame>
    <description>Change from Baseline in PASI score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Area and Severity Index (PASI) -50</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Percent of patients who achieved PASI-50</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis Area and Severity Index (PASI) -75</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Percent of patients who achieved PASI-75</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Assessment (PGA)</measure>
    <time_frame>Baseline to Weeks 4, 8 and 12</time_frame>
    <description>Change from Baseline in PGA score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Assessment (PGA)</measure>
    <time_frame>Week 12</time_frame>
    <description>Percent of patients who achieve PGA score of 0 or 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psoriasis-Affected Body Surface Area (BSA)</measure>
    <time_frame>Baseline to Weeks 4, 8 and 12</time_frame>
    <description>Change from Baseline in Psoriasis-Affected BSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measure through incidence of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>The number of patients experiencing TEAEs and number of individual TEAEs will be summarized among treatment arms, by system organ class (SOC) and PT. TEAEs will also be summarized among treatment arms, by severity and by relationship to study drug.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Psoriatic Plaque</condition>
  <arm_group>
    <arm_group_label>Low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>39 subjects for low dose group. 26 subjects on KBL697, 13 subjects on placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>39 subjects for high dose group. 26 subjects on KBL697, 13 subjects on placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KBL697</intervention_name>
    <description>1 capsule BID of KBL697 or Placebo</description>
    <arm_group_label>Low dose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KBL697</intervention_name>
    <description>5 capsules BID of KBL697 or Placebo</description>
    <arm_group_label>High dose group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, aged 18 to 75 years (inclusive)&#xD;
&#xD;
          -  Have a diagnosis of plaque type psoriasis for â‰¥ 6 months&#xD;
&#xD;
          -  Must have chronic plaque type psoriasis of moderate severity&#xD;
&#xD;
          -  All subjects must agree and commit to the use of a reliable contraceptive regimen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current diagnosis of forms of psoriasis other than chronic plaque type only&#xD;
&#xD;
          -  Drug-induced psoriasis&#xD;
&#xD;
          -  Other inflammatory skin disease that may confound the evaluation of plaque psoriasis&#xD;
&#xD;
          -  Failed 2 or more systemic treatments for plaque psoriasis&#xD;
&#xD;
          -  Medicinal shampoos that contain tar and/or salicylic acid within 2 weeks prior to&#xD;
             Baseline Visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sangwoo Lee</last_name>
    <phone>+82 2 8889964</phone>
    <email>swlee@kobiolabs.com</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 9, 2021</study_first_submitted>
  <study_first_submitted_qc>May 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>microbiome</keyword>
  <keyword>KBL697</keyword>
  <keyword>Plaque psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

